Table 4.
Objective response rates by clinical characteristics, HER2 status, and p53 status
| Variable | Number of patientsa | Response rate (%) | P valueb |
| Age | 0.045 | ||
| >50 years | 108 | 29 | |
| ≤50 years | 50 | 14 | |
| Performance status | 0.81 | ||
| 0 | 77 | 23 | |
| 1 or 2 | 80 | 25 | |
| ER | 0.056 | ||
| Positive | 70 | 17 | |
| Negative | 71 | 31 | |
| PR | 0.51 | ||
| Positive | 64 | 22 | |
| Negative | 71 | 27 | |
| ER/PR | 0.22 | ||
| At least 1 positive | 81 | 20 | |
| Both negative | 59 | 29 | |
| Number of metastatic sites | 0.50 | ||
| 0–2 | 139 | 25 | |
| >2 | 17 | 18 | |
| Disease-free interval | 0.10 | ||
| ≤2 years | 101 | 20 | |
| >2 years | 57 | 32 | |
| Prior adjuvant chemotherapy | 0.83 | ||
| Yes | 94 | 24 | |
| No | 61 | 23 | |
| HER2 CBll | 0.96 | ||
| Positive | 30 | 23 | |
| Negative | 126 | 24 | |
| HER2 FISH | 0.70 | ||
| Positive | 37 | 22 | |
| Negative | 109 | 25 | |
| HER2 HercepTest | 0.026 | ||
| Positive: 2–3 | 46 | 35 | |
| Negative: 0–1 | 105 | 18 | |
| HER2 HercepTest | 0.98 | ||
| Positive: 3 | 30 | 23 | |
| Negative: 0–2 | 121 | 23 | |
| p53 IHC | 0.79 | ||
| Positive | 56 | 23 | |
| Negative | 89 | 21 | |
| p53 Mutation | 0.55 | ||
| Present | 42 | 21 | |
| Absent | 103 | 26 |
aNot all patients could be evaluated for a response, and those who could not be evaluated have been excluded. bP values are for comparisons of the proportion of patients with a response to paclitaxel in each group. ER, estrogen receptor; FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; PR, progesterone receptor.